Search Results (154)

Background/Objectives: Multifactorial prevention of falls in persons with dementia has minimal or non-significant effects. Personalised prevention is recommended. We have previously shown that gait speed, basic activities of daily living (ADL), and depression (high Cornell scores) were independent predictors of falls in persons with mild and moderate cognitive impairment. This study explored person-specific risks of falls related to physical, mental, and cognitive functions and types of dementia: Alzheimer’s disease (AD), vascular dementia (VD), mixed Alzheimer’s disease/vascular dementia (MixADVD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). Methods: The study used data from “The Norwegian Registry of Persons Assessed for Cognitive Symptoms” (NorCog). Differences between the dementia groups and predictors of falls, gait speed, ADL, and Cornell scores were analysed. Results: Among study participants, 537/1321 (40.7%) reported a fall in the past year, with significant variations between dementia diagnoses. Fall incidence increased with age, comorbidity/polypharmacy, depression, and MAYO fluctuation score and with reduced physical activity, gait speed, and ADL. Persons with VD and MixADVD had high fall incidences and impaired gait speed and ADL. Training of physical fitness, endurance, muscular strength, coordination, and balance and optimising treatment of comorbidities and medication enhance gait speed. Improving ADL necessitates, in addition, relief of cognitive impairment and fluctuations. Relief of depression and fluctuations by psychological and pharmacological interventions is necessary to reduce the high fall risk in persons with DLB. Conclusions: The fall incidence and fall predictors varied significantly. Personalised interventions presuppose knowledge of each individual’s fall risk factors. Full article

This narrative review examines the effects of caffeine on brain health in older adults, with particular attention to its potential for dependence—an often-overlooked issue in geriatric care. Caffeine acts on central adenosine, dopamine, and glutamate systems, producing both stimulating and rewarding effects that can foster tolerance and habitual use. Age-related pharmacokinetic and pharmacodynamic changes prolong caffeine’s half-life and increase physiological sensitivity in the elderly. While moderate consumption may enhance alertness, attention, and possibly offer neuroprotective effects—especially in Parkinson’s disease and Lewy body dementia—excessive or prolonged use may lead to anxiety, sleep disturbances, and cognitive or motor impairment. Chronic exposure induces neuroadaptive changes, such as adenosine receptor down-regulation, resulting in tolerance and withdrawal symptoms, including headache, irritability, and fatigue. These symptoms, often mistaken for typical aging complaints, may reflect a substance use disorder yet remain under-recognized due to caffeine’s cultural acceptance. The review explores caffeine’s mixed role in neurological disorders, being beneficial in some and potentially harmful in others, such as restless legs syndrome and frontotemporal dementia. Given the variability in individual responses and the underestimated risk of dependence, personalized caffeine intake guidelines are warranted. Future research should focus on the long-term cognitive effects and the clinical significance of caffeine use disorder in older populations. Full article

Background/Objectives: The prognostic uncertainty of Mild Cognitive Impairment (MCI) imposes comprehensive neuropsychological evaluations beyond mere memory assessment. However, previous investigations into other cognitive domains, such as attention, have yielded divergent findings. Furthermore, while evidence suggests the presence of sex differences across the spectrum of dementia-related conditions, no study has systematically explored attentional disparities between genders within this context. The current study aims to investigate differences in the attentional subcomponents, i.e., alerting, orienting, and executive control, between patients with MCI and healthy older controls (HOCs), emphasizing interactions between biological sex and cognitive impairment. Methods: Thirty-six participants (18 MCI, and 18 HOCs) were evaluated using the Attention Network Test (ANT). Raw RTs as well as RTs corrected for general slowing were analyzed using Generalized Mixed Models. Results: Both health status and sex influenced ANT performance, when considering raw RTs. Nevertheless, after adjusting for the baseline processing speed, the effect of cognitive impairment was no longer evident in men, while it persisted in women, suggesting specific vulnerabilities in females not attributable to general slowing nor to the MCI diagnosis. Moreover, women appeared significantly slower and less accurate when dealing with conflicting information. Orienting and alerting did not differ between groups. Conclusions: To the best of our knowledge, this is the first study investigating sex differences in attentional subcomponents in the aging population. Our results suggest that previously reported inconsistencies about the decline of attentional subcomponents may be attributable to such diversities. Systematically addressing sex differences in cognitive decline appears pivotal for informing the development of precision medicine approaches. Full article

Depression and cognitive impairment frequently co-occur in older adults, but their temporal relationship remains unclear. While depression is often considered a risk factor for cognitive decline, evidence is mixed, particularly in individuals with mild cognitive impairment or early dementia (MCI/ED). This study analyzed longitudinal data from 1086 participants (M = 74.49, SD = 7.24) in the SMART4MD clinical trial, conducted in Spain and Sweden over 18 months, with assessments every six months. Cognitive impairment was measured using the Mini-Mental State Examination, and depression was assessed with the Geriatric Depression Scale-15. Findings revealed a concurrent association between depressive symptoms and cognitive impairment. In regression mixed analysis, depression levels predicted increased cognitive decline over time, but no evidence was found for cognitive impairment predicting future depression. These associations were confirmed using a bivariate latent growth curve model with cross-lagged paths, which revealed early but attenuating bidirectional effects between depression and cognition. These results highlight depression as a medium-term risk factor for cognitive decline, emphasizing the importance of addressing depressive symptoms to mitigate cognitive deterioration in MCI/ED populations. Full article

Bidirectionality between insomnia and depression is well documented in general and clinical populations but remains under-researched in family caregivers of people with dementia. This study aimed to explore this relationship using a longitudinal design with 155 family caregivers assessed annually over three years. Data collected included sociodemographic information, health behaviors, medical data, caregiving stressors, and depressive and insomnia symptoms. Two linear mixed models were tested: Model 1 considered insomnia symptoms as the independent variable and depressive symptoms as the outcome; Model 2 considered depressive symptoms as the independent variable and insomnia symptoms as the outcome. The results showed that caregivers with more insomnia symptoms over time had significantly higher depressive symptoms, even after adjusting for covariates. Insomnia accounted for an additional 7.47% of the variance, with a total explained variance of 57.93%. Conversely, higher depressive symptoms over time were associated with increased insomnia. Depressive symptoms explained an additional 7.28% of the variance, with a total explained variance of 25.74%. These results were consistent with previous studies on non-caregiving populations, adding empirical evidence to the notion that both insomnia and depression may operate as a risk factor for the other disorder. Caregiver support interventions could improve their psychological well-being if they incorporate sleep-focused strategies. Full article

Transactive response DNA-binding protein of 43 kDa (TDP-43) and tau proteins play critical roles in neurodegenerative diseases, particularly frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD). The co-occurrence of TDP-43 and tau pathologies raises questions about their role in disease progression. This review explores the simultaneous presence of tau and TDP-43 co-pathologies, emphasizing their molecular interactions and the resultant neuropathological implications. Additionally, we provide representative examples of their clinical presentations, neuroimaging, and neuropathological findings associated with FTLD-TDP and FTLD-tau, emphasizing the need for a comprehensive understanding of these intertwined pathologies. We analyze various clinical scenarios, including argyrophilic grain disease (AGD), primary age-related tauopathy (PART), and limbic predominant age-related TDP-43 encephalopathy (LATE), to elucidate the complex relationship between these proteinopathies. From the literature, the co-occurrence of tau and TDP-43 is linked to more severe and poorer clinical outcomes compared to isolated pathologies. This review underscores the necessity of considering co-pathologies in the context of FTLD, as they may act as accelerators of cognitive decline. This highlights the importance of integrated approaches in diagnosing and treating neurodegenerative conditions characterized by tau and TDP-43 misfolding. Understanding the interplay between these molecular markers is vital for advancing therapeutic strategies for such disorders. Full article

This review aimed to identify the available online interventions for family carers of people living with dementia and how effective they are when upskilling carers in how to support activities of daily living. Six databases were searched, and 10 articles with six online programmes were identified. Articles used an RCT design, a mixed approach, and a pre-post test design. Data were synthesised using a convergent integrated approach for mixed-methods reviews. Three overarching themes were identified, focusing on accessibility of the programme, the content and information provided, and the outcomes for the carer and the person with dementia. Online interventions with useful content for family carers of people with dementia are easy to access. However, this did not translate into carers’ outcomes, where mixed results were found. No positive findings were reported for people with dementia in terms of social participation, autonomy or self-management abilities. Development of future online interventions should consider integrating carers’ competence, skills and knowledge alongside daily activities to provide a comprehensive approach when training family carers. Full article

As Taiwan is about to enter a super-elderly society (the elderly over 65 years old account for more than 20% of the total population), how to delay disability and dementia in the elderly has become an important issue. Increasing the use of toys and games for the elderly delays their disability. Therefore, we developed three 3D interactive games for the elderly using mixed-reality (MR) technology. The three games were designed for hand-eye coordination, including digital cognition, object shape recognition, and color recognition ability. The reaction time was recorded to analyze the elderly’s reaction ability when playing the games. The questionnaire survey results showed that more than 83% of the elderly were satisfied with the use of MR equipment. More than 87% of the elderly accepted the interactive mechanism of MR while more than 80% felt that the three games improved their reaction ability. Full article

Aim: To understand dementia care knowledge, attitudes, and confidence among acute-care support staff following a dementia education intervention titled Dementia Workforce Excellence in Acute Care. Design: A convergent parallel mixed-methods pilot study. Methods: Data were collected from 30 participants using an online survey and three individual interviews between January and March 2024. Survey data were analysed using descriptive statistics, and a thematic analysis underpinned by Kirkpatrick’s framework was used to analyse the qualitative data from interviews. Results: The online survey established good levels of dementia knowledge, attitudes, and confidence among support staff with enhanced attitudes among staff who completed the training. Analysis of interviews resulted in three themes: dementia in the acute care setting; motivation for learning; and evaluation of the intervention on four levels [satisfaction, learning gains, behaviours, and results]. Conclusion: Findings suggest that the dementia education intervention used in this study is a comprehensive dementia training resource that promotes person-centred and compassionate dementia care across all stages of the dementia journey. Dementia is a public health priority with workforce education identified as a key response for capacity building. This pilot evaluation offers insight and new learning on the pedagogical approaches that are inclusive of peer-supported reflective learning in small groups that remain untapped for dementia workforce development. Dementia inclusive and enabling environments with a knowledgeable and skilled workforce are crucial to mitigate stigma and discrimination. This can be best achieved by raising awareness through targeted staff education and training to make hospital environments more dementia inclusive. Patient or Public Contributions: Dementia care scenarios used in this study were co-designed by experts with lived experience of dementia. Additionally, these experts along with family carers of people living with dementia were involved in the delivery of the training where appropriate. Full article

Background: Dementia is a global condition affecting over 55 million people. Since there is no treatment, non-pharmacological interventions aim to delay its progression in a safe and cost-effective way. The extant literature suggests that Positive Psychology Interventions (PPIs) can probably be effective for this purpose. The systematic review aims to assess the effectiveness of PPIs as non-pharmacological interventions for mild cognitive decline related to dementia by evaluating their effectiveness in cognitive functions and brain functioning in people with Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and mild Alzheimer’s disease dementia (AD). Methods: A comprehensive search conducted in the databases Scopus, PubMed, ScienceDirect and PsychINFO (December 2024–March 2025) published between 2015 and 2025 to identify records that met inclusion criteria: studies included patients with SCD, MCI and mild AD dementia, implemented PPIs, Randomized controlled trials (RCTs) and pre–post intervention studies with measurable outcomes, assess at least one of the following: cognitive functions and brain functioning. Results: The systematic review included 12 studies (N = 669 participants) that can answer the research question. Only mindfulness interventions were identified. Findings suggest that different types of mindfulness interventions, such as the Mindfulness Awareness Program (MAP) and Mindfulness Training (MT), may be efficient for improving specific cognitive functions (e.g., working memory and attention) and influencing biological pathways related to cognitive decline. However, long-term efficacy has not been demonstrated, and results are mixed and unclear. Conclusions: Μindfulness interventions seem promising for enhancing cognition and brain functioning in older adults with cognitive decline, although the data is limited. However, limitations such as the heterogeneity of the studies and the diversity of the interventions make it necessary for more systematic and organized research to be conducted on the implementation of such interventions. At the same time, it is proposed to examine the effectiveness of other constructs of positive psychology, such as character strengths (CS). Full article

Physical function is likely bidirectionally associated with physical activity (PA), sedentary behavior (SB), and sleep. We examined trajectories of physical function as predictors of these behaviors in community-dwelling adults aged ≥65 y without dementia from the Adult Changes in Thought cohort. Exposures were trajectories of physical performance (short Performance-Based Physical Function [sPPF]) and self-reported activities of daily living (ADL) impairment. Outcomes were device-measured PA and SB and self-reported sleep. We fit linear mixed-effects models to define trajectory slopes and intercepts for each functional measure over the prior 10 years. We used multivariable linear regression to investigate the relationship between trajectory features and outcomes, using bootstrap confidence intervals. Participants (N = 905) were 77.6 (SD = 6.9) years old, 55% female, 91% white, and had a median sPPF score of 9 (IQR = [8, 11]) and median impairment of 1 ADL (IQR = [0, 2]) at the time of activity measurement (baseline). Steeper decreases in sPPF (0.3-unit, 25% of the range) were associated with fewer steps (−1180, 95% CI = [−2853, −185]) and less moderate-to-vigorous PA (−15.7 min/day [−35.6, −2.3]). Steeper increases in ADL impairment were associated with 35.0 min/day (4.3, 65.0) additional sitting time, longer mean sitting bout duration (3.5 min/bout [0.8, 6.2]), fewer steps (−1372 [−2223, −638]), less moderate-to-vigorous PA (−13 min/day [−22.6, −5.0]), and more time-in-bed (25.5 min/day [6.5, 43.5]). No associations were observed with light PA or sleep quality. Worsening physical function is associated with lower PA and higher SB, but not with light-intensity movement or sleep quality, supporting the bidirectional nature of the relationship between physical function and physical behaviors. Full article

Background/Objectives: The ERlangen Score (ERS) and the pTau/Aβ1-42 ratio are dementia risk scores that use only surrogate markers of amyloid and tau pathology, whose performance has taken on added importance with the advent of anti-amyloid antibody therapies. Direct comparisons between the scores are limited, which is why the performance of the ERlangen Score (ERS) and the pTau/Aβ1-42 ratio in predicting cognitive decline and dementia risk were compared. Methods: Measurements of Aβ1-42, Aβ1-40, and pTau181 were conducted in cerebrospinal fluid samples using immunoassays. Linear mixed models and the area under the receiver operating characteristic curve (AUC, receiver operating characteristic = ROC) of 259 non-demented subjects were calculated. Results: The pTau/Aβ1-42 ratio correctly identified 55 out of 60 individuals with a positive Aβ1-42/Aβ1-40 ratio and pTau181 as having Alzheimer’s disease (AD), while the ERS correctly identified all of these individuals. The model using the ERS to predict cognitive trajectories (Akaike Information Criterion AIC = 2365) exhibited a marginally superior fit than the model using the pTau/Aβ1-42 ratio (AIC = 2371). There was no statistically significant difference in the AUC of the ERS (0.717) for dementia risk compared to the pTau/Aβ1-42 ratio (0.739), p = 0.179. However, when the Aβ1-42/Aβ1-40 ratio was not included in the ERS (AUC = 0.685), the pTau/Aβ1-42 score was found to be statistically significantly better, p = 0.007. Conclusions: The ERS showed an advantage in grouping, identifying all patients with a positive Aβ1-42/Aβ1-40 ratio and elevated pTau181 as having AD. The ERS and pTau/Aβ1-42 ratio were comparable in predicting dementia or cognitive decline. However, when the Aβ1-42/Aβ1-40 ratio is not available, the pTau/Aβ1-42 ratio should be preferred. Full article

Background and Objective: Primary Progressive Aphasias (PPAs) are rare neurodegenerative disorders classified within frontotemporal lobar degeneration (FTLD) and typically manifest between 45 and 70 years of age. In Mexico—and many other countries—reliable epidemiological data are lacking; however, estimates suggest that PPA accounts for 0.5–2.5% of neurodegenerative disease cases in Memory Clinics, with an incidence of approximately 1 per 100,000 and an average survival of 8 years. This review aims to provide clinicians with an overview of PPA’s epidemiology, clinical features, and classification, thereby enhancing understanding of its subtypes and distinguishing characteristics from other aphasic conditions, such as vascular aphasia. Methods: This narrative review was conducted through a literature search using databases such as PubMed and Scopus. Relevant studies addressing the epidemiology, clinical presentation, and classification of PPA were identified, selected, and synthesized to offer a broad, clinically oriented overview of the condition. This approach was chosen to inform clinical practice and highlight the need for further targeted investigations, such as future systematic reviews focusing on specific aspects like therapeutic strategies. Key Contents and Findings: (a) Epidemiology: PPA is estimated to affect 0.5–2.5% of patients with neurodegenerative diseases in Memory Clinics, with an incidence of roughly 1 per 100,000. Average survival time is around 8 years (ranging from 3 to 17 years), with a generally balanced gender ratio, though some studies indicate a predominance of men. A positive family history is observed in 20–40% of cases, with about 10% following an autosomal dominant inheritance pattern. (b) Clinical Characteristics and Classification: PPA is marked by a gradual decline in language abilities, differentiating it from vascular aphasias. Subtypes include non-fluent forms (non-fluent progressive aphasia [nfPPA] and logopenic progressive aphasia [lPPA]), fluent forms (progressive fluent aphasia [PFA] and semantic dementia [SD]), and mixed forms (progressive mixed aphasia [PMA]). The neurodegenerative process in PPA extends beyond vascular boundaries, often resulting in presentations that deviate from classical Broca’s and Wernicke’s aphasias. Common symptoms include difficulties in word finding and naming, sometimes mistaken for memory loss, and, in the case of semantic dementia, personality changes that may go unnoticed by the patient. Conclusions: PPA is a heterogeneous and complex group of neurodegenerative disorders with significant clinical variability and a profound impact on patients and their families. While current epidemiological data are limited, this review emphasizes the need for further research to better delineate disease progression and refine diagnostic and therapeutic approaches. Future systematic reviews will be essential to address specific aspects of PPA, such as treatment strategies, to further improve patient care. Full article

Depositions of protein aggregates are typical pathological hallmarks of various neurodegenerative diseases (NDs). For example, amyloid-beta (Aβ) and tau aggregates are present in the brain and plasma of patients with Alzheimer’s disease (AD); α-synuclein in Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA); mutant huntingtin protein (Htt) in Huntington’s disease (HD); and DNA-binding protein 43 kD (TDP-43) in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). The same misfolded proteins can be present in multiple diseases in the form of mixed proteinopathies. Since there is no cure for all these diseases, understanding the mechanisms of protein aggregation becomes imperative in modern medicine, especially for developing diagnostics and therapeutics. A Multimer Detection System (MDS) was designed to distinguish and quantify the multimeric/oligomeric forms from the monomeric form of aggregated proteins. As the unique epitope of the monomer is already occupied by capturing or detecting antibodies, the aggregated proteins with multiple epitopes would be accessible to both capturing and detecting antibodies simultaneously, and signals will be generated from the oligomers rather than the monomers. Hence, MDS could present a simple solution for measuring various conformations of aggregated proteins with high sensitivity and specificity, which may help to explore diagnostic and treatment strategies for developing anti-aggregation therapeutics. Full article

Dementia is recognised as a disability under the United Nations Convention on the Rights of Persons with Disabilities (UNCRPD). People with disabilities like dementia have the right to access specialised health and social care services, including interventions that support independence and community participation. Cognitive Stimulation Therapy (CST) is an evidence-based psychosocial intervention that improves cognition, communication, confidence, and quality of life for people living with dementia, but an implementation gap means that CST is often not available. This study examines whether trained CST practitioners implemented CST, their perceptions of the acceptability and efficacy of CST, whether the perceived acceptability and efficacy of CST predicted implementation, and practitioners’ opinions on the barriers and facilitators to CST implementation. A mixed-methods approach was used, with 62 participants (91.9% female). Although 95% of participants were trained to deliver CST, 45.2% did not facilitate CST groups. Statistical analysis showed that perceived efficacy significantly predicted both the likelihood of running CST groups (p = 0.006) and the number of groups delivered (p = 0.01). Thematic analysis of qualitative data identified the three key themes of ‘resources’, ‘awareness and education’, and ‘acceptability of CST’. Overall, the results show that while CST is acceptable and deemed highly effective, resources and staffing often impede implementation. The results are discussed in the context of prioritising the rights of people with disabilities and recommendations are made on improving access to evidence-based support. Full article